Press releases
- Insulet to Present at the Jefferies Global Healthcare Conference
- Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
- Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
- Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
- Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
- Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
More ▼
Key statistics
On Monday, Insulet Corp (P2OD34:SAO) closed at 31.41, -2.42% below its 52-week high of 32.19, set on Feb 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.41 |
---|---|
High | 31.41 |
Low | 31.41 |
Bid | 30.96 |
Offer | 35.00 |
Previous close | 31.41 |
Average volume | 500.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 21 2024 00:00 BST.
More ▼